Reducing Influenza Duration, Related Complications and Healthcare Costs with Novel Antivirals

https://www.pharmacytimes.org/on-demand/ajmc-payer-forum-reducing-influenza-duration-related-complications-and-healthcare-costs-with-novel-antivirals

Related Videos

Related Content

Advertisement

June 13th 2025

First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

Jared Kaltwasser

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 13th 2025

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

Jordyn Sava

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 13th 2025

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results

Christina Mattina

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

June 13th 2025

Pediatric Atopic Dermatitis Linked to Allergy Development

Maggie L. Shaw

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

Related Content

Advertisement

June 13th 2025

First-Line Ibrutinib Effective in CLL/SLL With or Without Risk Factors

Jared Kaltwasser

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 13th 2025

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

Jordyn Sava

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 13th 2025

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results

Christina Mattina

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

June 13th 2025

Pediatric Atopic Dermatitis Linked to Allergy Development

Maggie L. Shaw

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.